5月28日，晶泰控股盘中上涨5.09%，报8.47港元，成交额1.52亿港元。
消息面上，公司公告与DoveTree的合作进展理想，其中一个泛癌种驱动高价值资产已率先进入临床申请前准备研究阶段，在初步生物学活性验证中展现出明确的靶点干预效应和优异的选择性窗口。此前集团已收到该协议项下约5,100万美元首付款。此外，公司三位联合创始人温书豪、马健及赖力鹏已自愿将禁售承诺延长至明年6月12日，涉及约12.9%股权，彰显对公司长远价值的信心。
晶泰控股是一家主要从事为制药及材料科学等产业提供药物及材料科学研发解决方案及服务的控股公司，业务涵盖药物发现解决方案及智能自动化解决方案。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.